Minimal Residual Disease Evaluation in Childhood Acute Lymphoblastic Leukemia: A Clinical Evidence Review.
CONCLUSIONS: Minimal residual disease is an independent prognostic factor for relapse in childhood ALL. Relapse is a key determinant of EFS and patients' quality of life. Treatment selected on the basis of MRD status appears to improve outcomes.
PMID: 27099643 [PubMed - in process]
Source: Ontario Health Technology Assessment Series - Category: Journals (General) Tags: Ont Health Technol Assess Ser Source Type: research
More News: Acute Leukemia | Acute Lymphoblastic Leukemia | Cancer | Cancer & Oncology | Childhood Cancer | General Medicine | Health | Leukemia | Molecular Biology | Stem Cell Therapy | Stem Cells | Study | Transplants